Loading stock data…
GH
$87.60+0.52 (+0.60%)
Market ClosedLast close May 1
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Guardant Health, Inc. in the Healthcare sector is trading at $87.60. The stock is currently 27% below its 52-week high of $120.74, remaining 4.8% above its 200-day moving average. Technical signals show neutral RSI of 60 and bullish MACD crossover, explaining why GH maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 60) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$87.60
Potential Upside
5%
Whystock Fair Value$91.98
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus21 analysts
Mean target$128.33+46.5%
Range$90.00 – $180.00
Fundamentals
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liqu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$11.75B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.65
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
416.71%
Volume
Today's trading volume
1.11M
Recent News
Guardant Health (GH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Guardant Health, Organon, Fortrea, QuidelOrtho, and Charles River Laboratories Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after a proposed 2027 federal budget revealed significant spending cuts for key health agencies.
Guardant Health (GH) Valuation Check After Strong 1 Year Return And Recent 90 Day Pullback
Guardant Health (GH) has drawn fresh attention as investors look at its recent share performance alongside its growing precision oncology business, including liquid biopsy tests and data services for cancer detection and treatment decisions. See our latest analysis for Guardant Health. At a latest share price of US$93.83, Guardant Health has seen a sharp 10.9% 7 day share price return and a 1 year total shareholder return above 100%. However, the 90 day share price return of a 7.77% decline...
1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have outperformed the market lately as the 1.1% drawdown for healthcare stocks over the past six months was relatively better than the S&P 500’s 2.8% decline.
What's Fueling TEM Diagnostics Segment's Strong 2026 Outlook?
TEM's diagnostics arm surges on oncology demand, MRD adoption and rising pricing, with 2026 growth set to stay strong as sequencing and reimbursement expand.